proteomic characterization of blood plasma is of central importance to clinical proteomics and particularly to biomarker discovery studies. the vast dynamic range and high complexity of the plasma proteome have, however, proven to be serious challenges and have often led to unacceptable tradeoffs between depth of coverage and sample throughput. We present an optimized sample-processing pipeline for analysis of the human plasma proteome that provides greatly increased depth of detection, improved quantitative precision and much higher sample analysis throughput as compared with prior methods. the process includes abundant protein depletion, isobaric labeling at the peptide level for multiplexed relative quantification and ultra-high-performance liquid chromatography coupled to accurate-mass, high-resolution tandem mass spectrometry analysis of peptides fractionated off-line by basic pH reversed-phase (brp) chromatography. the overall reproducibility of the process, including immunoaffinity depletion, is high, with a process replicate coefficient of variation (cV) of <12%. using isobaric tags for relative and absolute quantitation (itraQ) 4-plex, >4,500 proteins are detected and quantified per patient sample on average, with two or more peptides per protein and starting from as little as 200 ml of plasma. the approach can be multiplexed up to 10-plex using tandem mass tags (tMt) reagents, further increasing throughput, albeit with some decrease in the number of proteins quantified. In addition, we provide a rapid protocol for analysis of nonfractionated depleted plasma samples analyzed in 10-plex. this provides ~600 quantified proteins for each of the ten samples in ~5 h of instrument time.
IntroDuctIon
Blood is estimated to contain well over 10,000 distinct proteins (not counting proteoforms that are post-translationally modified), with concentrations spanning a dynamic range of 10-12 orders of magnitude 1, 2 . As it directly communicates with nearly all organs and tissues in the body and is one of the most easily accessible bodily fluids, blood and its liquid derivatives are thought to hold singular promise as a source of potential biomarkers. Indeed, the vast majority of existing clinical laboratory tests measure proteins, small molecules and other analytes in plasma or serum derived from whole blood. Despite decades of attempts to mine this biomarker resource, however, global-discovery plasma proteomics has met with limited success, in large measure because of low numbers of identified proteins (i.e., poor depth of detection). Individual studies of the plasma proteome have typically detected fewer than 1,000 proteins with high confidence 3, 4 . As part of the Peptide Atlas project, Farrah and colleagues developed a high-confidence list of 1,929 plasma proteins by re-analyzing 91 high-quality data sets using a common database search and analysis platform and a protein false discovery rate (FDR) of 1% 5 . Recent analysis of additional data sets allowed further expansion to more than 3,500 plasma proteins; however, only ~2,500 of these proteins were confidently identified with at least two peptides, the ~1,000 remaining having been identified using only a single peptide and therefore being of lower confidence 6 . By contrast, current expert proteomic analyses of cells and tissues routinely yield >10,000 distinct proteins identified with two or more peptides per protein [7] [8] [9] . This large disparity in depth of detection is believed to be because of both the greater range in abundance of proteins in blood as compared with other tissues and the presence of a handful of large, highly abundant blood proteins that, after enzymatic digestion, yield vast numbers of abundant peptides that interfere with detection of peptides derived from less-abundant plasma proteins 10 .
To increase the depth of detection in plasma, methods have been developed to remove the most highly abundant proteins and to partition the remaining proteins or peptides into fractions with reduced complexity and dynamic range before analysis by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Abundant protein depletion is now commonly done by immunoaffinity, with single depletion columns capable of removing the 6-20 dominant plasma proteins [11] [12] [13] . Considerably deeper (two to fivefold, depending on specific methods used) coverage of the plasma proteome is possible with more intensive depletion. For example, the IgY14-SuperMix tandem column system (Sigma) depletes ~60 highly to moderately abundant proteins in addition to the 14 most highly abundant proteins that are removed by the IgY14 column, enabling detection of proteins in the low nanogram/milliliter range 12, 13 .
Abundant protein depletion has been most often used together with off-line protein-or peptide-level fractionation before LC-MS/MS analysis. Speicher and co-workers investigated multiple post-depletion plasma fractionation strategies-including SDS-PAGE for protein-level fractionation and isoelectric focusing, and bRP for peptide-level fractionation 14 -and showed that increasing the number of fractions by any method improves the sensitivity of detection in plasma, with high-pH reversed-phase (RP) fractionation yielding the highest number of low-abundant proteins. Combining fractions from the early, middle and late portions of the high-pH RP gradient further increased the depth of detection and chromatographic resolution by better equalizing 1 the amount of peptide in each fraction and more uniformly distributing peptide retention times in the acidic-pH RP chromatographic separation that is done online to the MS 15, 16 . Although fractionation at the peptide level greatly increases the depth of analysis, a major drawback has been the significant increase in the amount of time it takes to analyze a single sample. This unfortunate tradeoff between depth and throughput has meant that studies in plasma proteomics that include relatively large numbers of samples (many tens to >100) typically have shallow depth of coverage (e.g., Cominetti et al. 17 and Dayon et al. 18 ), whereas studies emphasizing depth of coverage typically have small sample numbers (e.g., refs. [19] [20] [21] . Our prior labelfree workflow for biomarker candidate discovery in acute myocardial injury highlights this challenge of plasma proteomics 19 . After immunoaffinity depletion of the 14 most abundant proteins, peptides from each patient sample time point were partitioned using strong cation exchange chromatography (SCX) into 80 fractions, with each patient sample requiring 160 h of MS analysis time. Although the depth of analysis was good by contemporary standards (average of 900 proteins per sample using a minimum of two peptides for identification), the prohibitive analysis time severely constrained the number of samples that could be analyzed. Importantly, small sample numbers combined with the relative quantitative imprecision of a label-free workflow meant that only fold-changes >5× could be confidently considered differential (see Addona et al. 19 for details).
To simultaneously achieve more precise relative quantification and higher analysis throughput in biomarker discovery studies, chemical labeling using commercially available iTRAQ and TMT isobaric reagents [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] has begun to be used for plasma analysis. After the depletion of six abundant proteins, Cole et al. performed 8-plex iTRAQ labeling and SCX separation into 24 fractions, resulting in the quantification of ~900 proteins across 500 patient plasma samples spanning 72 iTRAQ experiments 34 . In the largest patient study yet reported, Cominetti et al. applied an automated plasma processing workflow that included depletion of 14 abundant proteins, 6-plex TMT peptide labeling and online LC-MS/MS analysis without fractionation to >1,000 patient samples 17, 18 . Although each sample required only 3 h of instrument time, this study identified only 365 proteins in total across all samples. In an inter-laboratory study organized by the Association of Biomolecular Resource Facilities, centrally processed plasma underwent IgY14-SuperMix depletion, iTRAQ 4-plex labeling and SCX peptide separation into 30 fractions before distribution to participating laboratories for analysis 35 . Between 1,200 and 1,700 proteins were identified in each of the laboratories using current-generation high-performance LC and MS instruments.
Development of the protocol
Although a wide range of methods have been explored for plasma processing and analysis, an optimal approach has yet to be defined. In developing a processing and analysis protocol, our goals were to achieve very deep and reproducible coverage of the plasma proteome with precise relative quantification. This would allow sensitive detection of differential protein abundance between samples while retaining sufficient throughput to develop reasonable statistics. To this end, we have evaluated and optimized methods for abundant protein depletion, off-line peptide fractionation, online peptide separation and MS analysis [36] [37] [38] . The integrated approach that we developed incorporates IgY14-SuperMix immunoaffinity depletion, chemical labeling of peptides with isobaric mass tags (using either iTRAQ or TMT), peptide-level fractionation using basic RP with a concatenated fraction-pooling strategy and LC-MS/MS analysis using long (>20 cm) columns packed with sub-2-µm beads coupled to current, high-performance hybrid mass spectrometers such as the Thermo Q-Exactive Plus (Fig. 1) . Figure 1 | Overview of multiplexed workflow for discovery proteomics in plasma. This figure shows application of the workflow to a specific study in which iTRAQ 4-plex reagent was used to process and analyze four time points of planned myocardial infarction (PMI) patient samples. However, as shown in the protocol, other depletion and labeling strategies can be used to accommodate the goals of a given study. HCD, higher energy collisional dissociation. Image adapted with permission from Keshishian et al. 38 , American Society for Biochemistry and Molecular Biology.
LC-MS/MS
To demonstrate the effectiveness of the workflow, we analyzed a time-course series of plasma samples using iTRAQ 4-plex labeling. The samples were obtained from patients undergoing therapeutic septal ablation (planned myocardial infarction (PMI)) for the treatment of hypertrophic obstructive cardiomyopathy 38 . An average of 4,600 proteins were confidently detected and quantified in each of 16 patient samples with a peptide FDR of < 1.5%. This is the largest number of proteins detected in a single study of the plasma proteome to date, and the deep coverage combined with the use of isobaric labeling enabled confident identification of >300 novel candidate biomarkers of acute myocardial injury-six times more than what was achieved in the prior label-free study 19 .
The protocol described here provides complete step-by-step instructions for achieving deep, quantitative analysis of the plasma proteome by mass spectrometry, with multiplexing of samples for improved sensitivity, decreased preanalytical variability and higher throughput. Measures of overall process reproducibility are provided, as are methods for assessing reproducibility of the depletion step. Substantial details about iTRAQ/ TMT-specific issues of data analysis are included. Although Spectrum Mill parameters and metrics are used as examples, the underlying concepts are described generally so that they can be applied when using other software packages that can handle iTRAQ/TMT data.
The protocol for deep, global analysis of plasma is illustrated using both 4-plex and 10-plex isobaric labeling strategies. A modified version of the protocol that enables, in principle, the analysis of up to 50 patient samples per day per instrument to a depth of ~600 proteins is also provided. All the methods described take advantage of the greater confidence in database searching provided by data collected at high resolution and accurate mass for both the intact precursor peptides and their fragment ions.
Although the current protocol focuses on the analysis of plasma, it can be adapted for the analysis of other biofluids, including cyst fluid, urine and cerebrospinal fluid, which also have populations of abundant proteins that overlap in identity with those found in plasma. Variations in total protein content and precise abundant protein composition in these fluids can be addressed with appropriate protocol modifications, including those in regard to intensity of depletion and extent of fractionation.
Current limitations and future directions
Using the workflow described here, it is possible to routinely detect and quantify >4,500 proteins per sample in plasma. Although this far exceeds what has been attained with other established workflows, it still represents at best 50% of the plasma proteome, and further advances, especially in detection of lowabundance proteins, are desirable. Improvements in both sample preparation strategies and MS instrumentation will move us closer to this goal. Although many such developments are on the near horizon, some are ready for immediate adoption. Among these are the use of small interior diameter (i.d.), ultra-highperformance LC columns for off-line basic pH reverse-phase fractionation and coupling of high-field asymmetric waveform ion mobility spectrometry (FAIMS) 39 to state-of-the-art MS instrumentation, both of which will help augment sensitivity for plasma analysis.
Experimental design
Starting material. The volume of starting plasma required is dependent on the depletion strategy, the intended plex level for labeling and the total protein amount required for off-line fractionation. The yield of protein from IgY14-depleted plasma is a minimum of ~3.5%, whereas IgY14-SuperMix tandem depletion yields a minimum of ~0.5%. Typically, 200 µl of plasma is required for IgY14-SuperMix depletion, but it is feasible to start with less ( Table 1) . This also has the advantage that smallercapacity, lower-cost, higher-throughput depletion columns may be used. The study detailed in the protocol analyzed plasma from patients undergoing a therapeutic, PMI for hypertrophic cardiomyopathy. In this nonsurgical procedure, alcohol is injected via a catheter into the heart (alcohol ablation) to cause selective destruction of the hypertrophied portion of the left side of the interventricular septum 37, 38 . In this study, we depleted 400 µl of plasma for each of the four time points (pre-alcohol ablation, and 10, 60 and 240 min post ablation) per patient using IgY14-SuperMix (Fig. 1) . This large volume was used because we wanted several additional depleted samples (per time point per patient) for future analyses and the sample was not limiting.
Protein amounts shown in Table 1 are based on a typical protein content of 70 mg/ml in plasma. It is important to check the plasma protein concentration upon which vendors base nominal column capacity and to adjust injection volumes accordingly if samples and IgY14-SuperMix columns will continue to deplete with good reproducibility over ~100 injections. To ensure this consistency for large studies (>100 samples), it is important to obtain an appropriate number of IgY14-SuperMix columns belonging to the same lot to avoid possible performance differences because of specific populations of antibodies. ReproSil-Pur, 120 Å, C18-AQ, 1.9-µm resin (Dr. Maisch, cat. no. r119.ag) EQUIPMENT Off-line HPLC system for plasma depletion and bRP separation: Agilent 1100 or 1200 series pump equipped with degasser, autosampler, UV detector, column-switching module and fraction collector. We use an Agilent 1200 system for plasma depletion and an Agilent 1100 system for bRP separation. Seppro IgY14 LC20 column (Sigma-Aldrich, cat. no. SEP000-1KT). This column will deplete the 14 most abundant proteins effectively for up to 300 µl of plasma at a 70 mg/ml concentration; however, for depletion of 400 µl of plasma, as described in this protocol, we used a custom 25-ml IgY14 column. The same HPLC method can be used for both columns with slight adjustment of fraction collection start time.  crItIcal Store the column at 2-8 °C.
MaterIals

REAGENTS
Seppro SuperMix LC10 column (Sigma-Aldrich, cat. no. SEP000-1KT) This column is not intended for stand-alone use but only for tandem depletion after IgY14 depletion. Its capacity is matched to the flow-through of the IgY14 LC20 column.  crItIcal Store the column at 2-8 °C. PEEK sample loop, 2 ml, 0.76 mm i. ; to make 1 liter, slowly add 27.8 ml of 28% (wt/vol) ammonium hydroxide to 500 ml of HPLC-grade water, then add ~45 ml of 10% (vol/vol) FA to bring the pH to 10; bring the final volume to 1 liter with HPLC-grade water.
bRP solvent A is 20 mM ammonium formate, pH 10, in 2% (vol/vol) acetonitrile.
bRP solvent B is 20 mM ammonium formate, pH 10, in 90% (vol/vol) acetonitrile.
bRP solvents are stable at RT for up to several days. UPLC-MS/MS solvents Solvent A is 0.1% (vol/vol) FA in 3% (vol/vol) acetonitrile and solvent B is 0.1% (vol/vol) FA in 90% (vol/vol) acetonitrile. UPLC solvents are stable for up to a month at RT. EQUIPMENT SETUP Plasma depletion setup on the Agilent 1200 system: tandem IgY14-SuperMix depletion To accommodate tandem column depletion, specific plumbing changes, modified methodologies and the use of a column-switching valve are required. Each are described below in detail. In addition, a simplified setup is also described for IgY14-only depletion.
Plumbing changes specific to the Agilent 1200 system are shown in Supplementary Figure 1 . Briefly, to increase the sample loop volume, replace the needle seat extension tubing with a 2-ml PEEK sample loop. Replace the following tubing: line 1 (from the purge valve/pump to port 1 on the injection valve), line 2 (from port 6 of the injection valve to top of the IgY14 depletion column), line 3 (from the bottom of the IgY14 column to port 4 of the column-switching valve), line 4 (port 5 of the columnswitching valve to the top of the SuperMix column), line 5 (from port 3 of the column-switching valve to the low dead volume T connector, which is also connected to the bottom of the SuperMix column) and line 6 (from the T connector to the detector) with 0.01-inch i.d., 1/16-inch o.d. PEEK tubing.  crItIcal It is important to note that, although our work was accomplished on an Agilent 1200 system, this procedure is universal to any high-pressure LC system. Loop capacity is ideal for 2-ml injection volumes, as neat plasma (maximum amount of 400 µl) must be diluted fivefold in 1× dilution buffer for optimal column performance. In addition, the inclusion of a 6-port column-switching capability between the tandem columns is
required. Any HPLC system that can accommodate these requirements and handle 500 p.s.i. (34 bar) column backpressure is suitable to accomplish this workflow. Injector-specific modifications to the Agilent 1200 system Because of limitations in loop sizes >900 µl on the Agilent system, the incorporation of the 2-ml needle seat extension is required to accommodate larger injection volumes. During method editing, replace the standard injector parameters in the 'Use injector' program with those shown in the table below. In this scheme, a coordinated injection protocol delivers three separate sample volumes from three separate, specifically located sample vials (vial positions 1 (750 µl), 3 (750 µl) and 5 (500 µl)) for a total of 2 ml injected per sample. Set the draw speed to 100 µl/min, eject speed to 100 µl/min and draw position to 1 mm in the 'general parameters' section.  crItIcal This protocol is written for a 400-µl neat plasma sample. If less material is to be depleted, the volumes and/or number of vials to be injected from can be modified. For example, if 200 µl of neat plasma is to be depleted, the final diluted plasma volume would be 1 ml, which could be injected from only two vials as 500-µl individual injections. Incorporation of column switching In the 'column thermostat' module of the method builder within the ChemStation vendor software, construct a timetable for column switching as shown in The goal is to use timed fractionation to collect the three eluted peaks: the flow-through (IgY14 and SuperMix depleted material), followed by the IgY14-bound material and, later, the SuperMix bound fraction. Figure 2 shows a typical UV trace at 280 nm. Plasma depletion setup on the Agilent 1200 system: IgY14-only depletion If IgY14-only depletion is desired, a simplified protocol can be constructed. Specific gradients for both tandem IgY14-SuperMix and IgY14 only are shown below. Each protocol uses the same regeneration method and the same customized injector protocol described above. Column switching is not used for IgY14-only depletion. However, the fractionation module is modified, as shown in the Preparing the system for depletion Once plumbing and method modifications are complete, purge all the solvent lines and then the entire system with water. Individually purge A1 with 1× dilution buffer, B2 with 1× stripping buffer and B1 with 1× neutralization buffer, each for 5 min at 5 ml/min. Run the dilution buffer for 15-30 min at 2 ml/min with no column. Connect the IgY14 and SuperMix columns and run the dilution buffer at 0.5 ml/min. Ramp up the flow rate to 2.0 ml/min and flush for another 30 min. If you are installing the column for the first time, run a blank injection before depleting samples.  crItIcal Depletion columns are stored at 4 °C indefinitely. They must reach RT before depletion. This can be achieved during the column flush. Do not exceed 34 bar of backpressure on the column. When depletion is complete, flush the column(s) with 1× dilution buffer containing 0.02% sodium azide for 30 min at 2 ml/min and store the columns at 4 °C.  crItIcal Antibody-based columns require specific handling and care. It is prudent to periodically check system and column performance by depleting a reference plasma sample (e.g., from a commercial source such as BioreclamationIVT). We typically run a reference sample as the first depletion when the column has been stored for longer than 1 month. This strategy also allows for troubleshooting of typical LC issues, including leaks, clogged lines and any errors in methodologies and proper fractionation before applying the methods to actual patient samples. Nanoflow C18 column The nanospray column for online UPLC-MS/MS analysis is self-packed into a 75-µm i.d. PicoFrit column with ReproSil-Pur resin (120 Å, C18-AQ, 1.9 µm) to a length of 20-24 cm using a pressure bomb set to 950 p.s.i. Chromatography gradients bRP chromatography blank gradient: timetable summarizing the gradient used for conditioning the column before injection of the sample at a flow rate of 200 µl/min (Step 57). 
No
Time interval (min) Gradient (%B)
0
Data-dependent (dd) settings
Underfill ratio 5%
Charge exclusion Unassigned, 1, ≥7
Peptide match Preferred
Exclude isotopes On Dynamic exclusion 20 s  crItIcal 17,500 resolution is used for MS2 in the experiments in which an iTRAQ or TMT-6 labeling strategy is used, as it provides enough resolution for resolving reporter ions. However, to resolve C and N series reporter ions for the TMT-10 labeling strategy, 35,000 resolution is used for MS2.  crItIcal We optimized collision energy for our instrument and used normalized collision energy (NCE) values of 27 and 29 for the iTRAQ and TMT tags, respectively. To achieve optimal fragmentation of iTRAQ-or TMT-labeled peptides, collision energy should be optimized on the instrument used for analyses of those samples.
proceDure plasma sample preparation for abundant protein depletion • tIMInG 30 min + overnight conditioning of concentrators 1| Prepare Millipore Amicon concentrators a day before the depleted samples are ready. Condition them by adding 2 ml of 0.1% (wt/vol) ODG solution to the concentrator and let them stand at RT overnight.  crItIcal step Passivation and preconditioning of concentrator membrane material is considered prudent in order to achieve minimal nonspecific peptide binding and subsequent loss.
2|
Remove a 3-to 5-µl unprocessed plasma pre-depletion sample. This sample can be stored at 2-8 °C for 24 h for measuring the pre-depletion protein concentration using a BCA assay at a later time point (Step 18). 3| Prepare dilution of plasma by adding 400 µl of plasma to 1,700 µl of 1× dilution buffer (Reagent Setup). An excess volume of 100 µl is included to account for sample volume losses during the spin filter step. The final effective dilution is slightly more diluted than the recommended fivefold dilution.
4|
Add 700 µl of diluted plasma to three separate 0.22-µm cellulose acetate spin filter tubes. Spin at 16,000g at 4 °C for 10 min.
5|
Transfer the combined flow-through from all spin filters and re-distribute into three separate 1-ml autosampler vials.  crItIcal step Some volume may be lost in the spin filters. Ensure that the final volume of diluted plasma in the three 1-ml autosampler vials is 780 µl, 780 µl and 530 µl (30 µl more than each of the three sample pickups; see Equipment Setup) for the user-defined injector sequence. If not, add 1× dilution buffer to compensate.
plasma depletion of highly abundant proteins • tIMInG 4 h 6| Highly abundant plasma proteins can be depleted either by using an IgY14 column (option A) or by using IgY14 and SuperMix tandem columns (option B).
(a) plasma depletion using only an IgY14 column • tIMInG 3 h per sample (i) For depletion of plasma using only the IgY14 column, use the step elution timetable and flow-rate settings outlined in the table below. Measure the UV absorbance at 280 nm. Depleted plasma elutes as a single peak from ~22 min to 35 min into 12-15 fractions, each containing 2 ml (Fig 2a) . (ii) Inject the sample. The depleted plasma elutes as a single peak from ~37 min to 52 min into 12-15 fractions, each containing 2 ml (Fig. 2b) . Fractions of the SuperMix-bound material must be collected only if the SuperMix column is being used as a form of abundance-based fractionation rather than for depletion.
7|
After each depletion step, regardless of depletion strategy, neutralize the acidic stripping conditions and re-equilibrate the column using the timetable outlined below before the next plasma sample is run. 
9|
Choose the fractions that contain the peak representing the depleted portion (typically distributed within 12 fractions). While selecting fractions, keep in mind that the total capacity of a single Amicon concentrator is no more than 15 ml. In this example, a sequence of two consecutive concentration steps, each with 12 ml, efficiently achieves this.
10|
Pipette the first six selected fractions into a single concentrator (12 ml). Keep the collection plate refrigerated during all spins to reduce any possible sample degradation.
11|
Centrifuge at 4,000g for 45 min at 4 °C. The sample retentate should be ~250 µl. Collect the filtrate and freeze it at −80 °C by placing it in the −80 °C freezer. This sample can be further analyzed (i.e., metabolite and/or small-molecule profiling) at a later time point.
12|
Add the next six selected fractions onto the retentate of each concentrator (12 ml).
13| Repeat
Step 11.
14|
In case more than 12 fractions are selected, repeat Steps 10 and 11 for the other fractions.
15| Perform a buffer exchange by adding 12 ml of the desired buffer (i.e., 50 mM ammonium bicarbonate with or without urea) to each concentrator. Centrifuge at 4,000g for 120 min at 4 °C.  crItIcal step Typically, 50 mM ammonium bicarbonate is used without urea. However, if digestion will immediately follow this step, urea can be added for a final concentration of 6 M.
16|
Transfer the retentate to a 1.5-ml tube. The sample volume should be ~250 µl. Rinse each concentrator by adding ~100-150 µl of additional exchange buffer and centrifuge at 4,000g for an additional 10 min at 4 °C. The goal is to rinse the membrane in order to optimize sample recovery while using minimal volume. We observe that most of the rinse volume is retained during this spin, probably because of the membrane condition at that stage.
17|
Transfer the sample retentate (~100 µl) to the previous sample retentate. The total volume should be ~ 300-350 µl. Add exchange buffer to achieve a final volume of 400 µl-the original plasma starting volume. If starting with another volume for plasma depletion (e.g., 200 µl or 300 µl), then after buffer exchange adjust the volume to be the same as the starting volume.
18| Perform a BCA assay to determine the protein concentration in both the depleted and the previously saved nondepleted plasma sample from Step 2. Dilute the nondepleted plasma sample 1:100 in 50 mM ammonium bicarbonate. IgY14-SuperMixdepleted samples can be assayed as a 1:2 dilution. For comparison, if IgY14 only is used for depletion, the proper dilution for post-depletion BCA would be 1:5. The final concentrations for IgY14-SuperMix-depleted samples are usually ~0.5-2% of the original 70 mg/ml of unprocessed plasma (0.35-1.4 mg/ml), whereas for IgY14 only the yield ranges from 3.5 to 5% (2.45-3.5 mg/ml 
24|
Further dilute the urea concentration to <1 M with 50 mM ammonium bicarbonate.
25| Add trypsin at an enzyme/substrate ratio of 1:50 and incubate at 37 °C with shaking on a table-top shaker set at 850 r.p.m. overnight (15−18 h).  crItIcal step Again, before incubation, check the pH with pH indicator strips to make sure that the pH is ~8. Adjust as needed with the addition of 1 M Tris buffer.
26| Quench the digestion with FA to a final concentration of 1%.
Desalting of digested plasma sample by spe • tIMInG 1 h per set of four samples + >3 h drying time  crItIcal We use Oasis HLB 1 cc (30 mg) SPE cartridges (Waters) for desalting 90-300 µg of plasma. The size of the cartridge should be adjusted when desalting less or more plasma sample. Waters recommends a sample capacity of 0.03-1% of total cartridge sorbent. Desalting is achieved using a Waters extraction manifold.
27|
Wash the cartridge three times with 500 µl of SPE solvent B (see Reagent Setup for SPE desalting solvents).  crItIcal step These volumes are designed to efficiently bind and elute the specified amount of protein content for a cartridge of this size. Use of smaller-or larger-capacity cartridges would require smaller or larger volumes. Check with the vendor for recommendations.
28|
Equilibrate the cartridge four times with 500 µl of SPE solvent A (see Reagent Setup for SPE desalting solvents).
29|
Load the digested sample and adjust the vacuum to ensure that the flow rate is very slow. We estimate our flow rate at ~1 drop in 2-3 s.
30|
Wash four times with 750 µl of solvent A.
31|
Elute three times with 500 µl of solvent B into single 1.5-ml Eppendorf tubes.
32|
Freeze the sample by placing it in a −80 °C freezer, and completely dry it via vacuum centrifugation.  pause poInt Samples can be frozen and stored at −80 °C for several weeks. 35| On the basis of the BCA results, make 100-µg aliquots of the digested sample, freeze them and completely dry them via vacuum centrifugation.  pause poInt Samples can be frozen by placing them in a −80 °C freezer and can be stored at −80 °C for several weeks.
labeling of the digested, depleted plasma samples 36| The digested plasma samples can be labeled using iTRAQ 4-plex reagent (option A) or using TMT-6 or TMT-10 reagent (option B). Selection of the labeling strategy is based on the study goal and the number of samples included in the multiplex experiment. iTRAQ 4 provides somewhat larger numbers of confident protein identifications, whereas TMT reagents allow higher multiplexing and throughput (see Anticipated Results below).
(a) itraQ labeling of digested, depleted plasma samples • tIMInG 1.5 h  crItIcal Labeling of plasma samples requires 2× more iTRAQ reagent than is typically used for peptide labeling in cell line or tissue extracts. On occasion, to achieve >95% labeling efficiency we have had to use additional reagent after label incorporation testing. stage-tip desalting • tIMInG 1 h 37| Prepare C18 stage tips by using Empore C18 extraction disks, as described by Rappsilber et al. 40 . Pack two plugs of C18 material into each stage tip (100-µl pipette tips) for a total binding capacity of ~25 µg total. Create extraction disks using a 16-gauge blunt-end metal needle to hole-punch the ~1-mm disks. We recommend using adaptors to the hold stage-tip pipette tip at the orifice of each 2-ml microcentrifuge tube.
38| Condition the stage tips with 100 µl of methanol. Centrifuge at 3,000g for 3 min at RT and discard the liquid from the collection vial. Repeat this step two times. All subsequent centrifugation steps for stage-tip desalting are for the same duration at the same speed and at RT. 42| Centrifuge the samples. Save the flow-through at 4 °C.  crItIcal step We typically save the flow-through of samples in case there is a catastrophic failure of the constructed stage tip. Recovery of the sample is not optimal but can be achieved. Once normal analysis of the sample is confirmed, the flow-through can be discarded.
43| Wash the samples twice with 100 µl of solvent A. Repeat the centrifugation step. Discard the liquid.
44|
Replace the collection vial with a new 1.5-ml screw cap vial for the collection of eluate.
45| Elute the sample with 60 µl of solvent B. Repeat the centrifugation step.
46|
Transfer the eluate to an HPLC vial, freeze it at -80 °C and completely dry it by vacuum centrifugation. 
47|
Data analysis and assessment of labeling efficiency • tIMInG 1 h 48|
In order to evaluate the completeness of free-amine labeling, configure the database searches to allow for both peptide N termini and lysine side chains to be present in either labeled or unlabeled form. With Spectrum Mill, accounting for partial labeling is accomplished with a fixed and mixed modifications search cycle strategy that runs a search four consecutive times with different sets of modifications in each round and then produces a single integrated output. The four cycles are as follows: (i) all unmodified, (ii) both peptide N termini and lysines labeled, (iii) only lysines labeled and (iv) only peptide N termini labeled. As the primary amine groups of lysine side chains (pKa ~10) are more reactive than peptide N-terminal amines (pKa ~7.5), incomplete labeling tends to be observed predominantly in the form of unlabeled peptide N termini. Furthermore, as long as a peptide includes at least one label, reporter ion quantification is viable. After running a four-cycle partial-labeling database search configuration with a suitable (1%) peptide spectral match (PSM)-level FDR threshold on a label-check aliquot, labeling efficiency percentage metrics are calculated in the Spectrum Mill Quality Metrics module: full label % = (100 × fully labeled PSMs)/total PSMs and label % = (100 × 1 or more labeled PSMs)/total PSMs.  crItIcal step We typically apply a threshold of 95% labeling. If the threshold is not met, then the samples will be re-labeled (see Troubleshooting section for relabeling procedure) before proceeding with further peptide-level fractionation. In our experience, TMT labeling is more robust and less likely to require re-labeling than iTRAQ labeling.
49|
Analyze the resulting mass spectrometry data from the mixing test sample to verify whether the total protein amount from each sample is the same. The Spectrum Mill Quality Metrics module does this by summing the reporter ion intensity (after applying isotopic correction) for each channel across all the confidently identified PSMs in the data set. Then, for each sample, the mixing percentages are calculated using the most abundant reporter ion channel sum as a common denominator, and each of the other channels as a numerator.  crItIcal step Unless particular samples are available in limited quantity, we require each sample to have a reporter ion intensity sum that is >50% of the most abundant sample. ? troublesHootInG
Quenching of labeling reactions • tIMInG 20 min+ >2 h drying time 50|
Once QC analysis is complete and shows satisfactory labeling (>95% labeling efficiency) and a 1:1:1:1 ratio in the mixing test, thaw the samples by placing them on ice. Step 62. We use 2.1 mm × 250 mm columns for bRP fractionation, which are suitable for 100-400 µg of total loading capacity; if you are working with lower amounts of total protein, the gradients are transferrable to 1 mm × 250 mm microscale separations run at 50 µl/min for up to a 50-µg total load.
56| Perform a QC of the HPLC system before fractionation. We typically accomplish this by injecting peptide standards in triplicate before running the actual sample. For this scale of bRP, 50 pmol of a mixture of seven in-house synthetic peptide standards is injected and evaluated for retention time reproducibility, signal intensity and peak resolution (Fig. 3a) . Selection of synthetic peptides should be based on their availability, as well as chromatographic behavior such as retention times spanning the duration of the gradient. For example, tryptic peptides of 10-15 aa in length with good solubility in aqueous buffer and consistent elution behavior on RP C18 are ideal. We choose peptides that are either from a species different from that of our sample of interest or that are isotopically labeled with heavy amino acids to reduce any contamination in subsequent runs on the column. In addition, column backpressure is informative for system performance. For this scale and configuration, backpressure is typically in the 90-110 bar range.
? troublesHootInG 57| Prepare the LC system for sample injection. Single sample separation consists of a sequence of two methods: blank gradient followed by the sample gradient. Once the QC of peptide standards indicates that the system is running properly, run a blank gradient to condition the column for the sample (see Equipment Setup). This is achieved by injecting 10 µl of bRP solvent A (refer to Reagent Setup for bRP solvents) from an HPLC vial with the gradient outlined below as blank gradient. Transfer 530 µl to the HPLC vial. Inject 500 µl.  crItIcal step Extra volume is needed to avoid injecting air bubbles into the system during the sample injection.
59|
For separation of iTRAQ-and TMT-labeled samples, use the corresponding gradient and flow-rate settings outlined in the tables in the Equipment Setup. For an example chromatogram, see Figure 3b ,c. In either bRP separation, 88 total fractions are collected into a Whatman 2-ml 96-well plate at a flow rate of 200 µl/min. For the iTRAQ-labeled sample, collection begins at 4 min, resulting in two fractions collected for the first 16 min (1.6 ml per well), followed by 84 fractions collected for 54 min (128.6 µl per well), followed by the final 10 min collected into two wells (1 ml per well). For the TMT-labeled sample, collection begins at 6 min, with the first 18 min collected into two wells (1.8 ml per well), followed by 52 min collected into 84 fractions (123.8 µl per well), followed by the final 14 min collected into two wells (1.4 ml per well).
60|
After separation, pool the bRP fractions (as described below) to generate 30 final fractions. The plate layout describes the recombination of wells, in which A1 is combined with H3 as fraction 1, A2 is combined with H4 as fraction 2, A3, C7 and E11 are combined as fraction 3 and so on (see the table below). Recombined pools for fractions 3 through 30 can be placed directly into HPLC vials (maximum volume is 400 µl) for reduced handling, although other vials with larger maximum volumes are commercially available.  crItIcal step Concatenation can be achieved into even smaller subsets depending on the number of final fractions desired. Our method reduces 84 individual wells to 28 final fractions (three wells with disparate hydrophobicity) plus 2 fractions from early and late portions of the chromatogram that are sparser in peptide content. For example, one could also recombine the 84 fractions into 12 repooled fractions by combining seven evenly distributed collected wells. 69| Set up the nanospray column packed to a 50-cm length (see Equipment Setup) with the column heater set to 50 °C.
70|
Set up the UPLC system with UPLC solvents A and B (see Reagent Setup for UPLC solvents).
71|
Before injection of the samples, run a QC test of the LC and MS performance by injecting a standard peptide mixture.
72| Inject 2 µl of the sample for LC-MS/MS analysis. The LC gradient used for this analysis is outlined in the Equipment Setup. Use the same MS parameters on the Q Exactive Plus MS system as described in the Equipment Setup.  crItIcal step Run a peptide QC sample after every six samples to clean the system and check the mass accuracy.
73|
Freeze the remaining sample for fractions by placing it in a −80 °C freezer space. 75| Analyze the final sample data set with a two-cycle fixed and mixed modifications search in Spectrum Mill. This option runs two consecutive searches with different sets of fixed modifications in each round and then produces a single integrated output. The two cycles allow for (i) both labeled peptide N termini and labeled lysines and (ii) only labeled lysines. Other search engines might allow similar strategies to be executed by configuring the label as a variable modification on peptide N termini and on lysines.
Data analysis
76| Correct the reporter ion intensities for isotopic impurities before using the reporter ion signals in each MS/MS spectrum for quantitative calculations 41 .  crItIcal step Each lot of reagent obtained from its manufacturer is accompanied by a certificate of analysis (this is also available on the manufacturer's website) that contains isotopic correction factors to be used by the quantification software. These correction factors are primarily used to account for naturally occurring levels of 13 C at the unlabeled carbons in the mass-tag portion of the labeling reagents. Because very-high-purity sources of 15 N and 13 C are routinely available and used for the labeled positions in the reagent, nearly full incorporation is typical. The correction factors provided by the reagent manufacturer represent mass spectrometry measurements of the isotope profile for each lot of reagent and thus co-mingle the contributions of unlabeled carbon and source of heavy isotope. Because there are more unlabeled carbons in the TMT structure than the iTRAQ structure, attention to isotopic correction to achieve accurate quantification is more important for TMT than for iTRAQ.  crItIcal step In complex samples such as plasma, the typical precursor mass window used for MS/MS (i.e., 0.7-3.0 m/z) passes more ions than just the dominant peak in any given m/z window. If these additional ions have an isobaric mass-tag reporter as part of the structure, then fragmentation of these ions will produce mass-tag ions that add to the reporter ion series from the dominant peak 29, 30 . As most peptides in a sample derive from proteins whose levels are not changing (or not changing significantly), the interfering signals from this background in every mass-tag channel compresses the observed ratios of regulated peptides/proteins in the samples. When combining reporter ion quantification from multiple PSMs to calculate the protein level, several software programs offer mechanisms to exclude PSMs that exhibit significant interference. A precursor ion purity filter is commonly used that determines the ratio of the intensity of the precursor ion and isotopes of the primary peptide identified in the MS/MS spectrum to the total intensity in the mass window isolated for precursor ion transmission 27, 42 . Use of a precursor ion purity of 50-70% is recommended. Various software packages use different mechanisms for combining the PSM-level measurements to determine the protein level from which the constituent peptides are derived. Spectrum Mill takes the ratios at the PSM level, and then calculates the protein-level ratio as the median of all PSM ratios 27 . This strategy diminishes the overall impact of outliers, but otherwise gives each PSM an equal contribution to the protein level ratio. Another common strategy is to sum the intensity for each reporter ion channel from the multiple PSMs contributing to the protein before taking the ratios. This strategy seeks to weight the contribution of each PSM by the reporter ion signal strength, with the implicit assumption that low-abundance signals are less accurate. Other variants of these basic approaches involve combining multiple PSMs to the peptide level first before calculating the protein level. These strategies seek to limit the bias of individual peptides that are observed in multiple PSMs because of different precursor charge states or sample-handling modifications.
? troublesHootInG Troubleshooting advice can be found in table 2. Figure 4 | Reproducibility of the plasma processing workflow. Five different aliquots of a pooled plasma sample were depleted using the IgY14-SuperMix tandem depletion strategy and digested. Single 30-µl aliquots of each of the four depletions and two aliquots of the fifth depletion were labeled using TMT6 reagent. After assessing labeling efficiency, the samples were mixed and desalted. The multiplexed sample was fractionated by basic pH reversed-phase chromatography and all 30 fractions were analyzed on a Q Exactive Plus mass spectrometer using in-house packed 75-µm ID picofrit columns packed with 1.9-µm beads to 20-cm length. Data analysis was done using a Spectrum Mill MS Proteomics Workbench. Proteinlevel total intensity as reported by Spectrum Mill was used for assessing reproducibility. contained >10 µg-a considerable excess, as we inject only a 1-2 µg total protein equivalent on 20 cm × 75 µm columns packed with sub-2-µm beads for LC-MS/MS analysis. As little as 100 µl of starting plasma volume would provide equivalent analysis depth and a sufficient amount of sample (after all sample processing) for a replicate injection, if required (table 1). Using the workflow described above, including IgY14-SuperMix depletion, an average of 4,600 proteins were confidently detected and quantified in each of 16 patient samples with peptide FDRs <1.5% (supplementary Fig. 3) . The anticipated number of confidently identified and quantified proteins reduces to an average of 2,500 with the less intensive IgY14-only depletion 38 .
Fractionating multiplexed samples by bRP chromatography reduces the complexity of the sample, therefore increasing the total number of identifications. The gradients for separation of iTRAQ-4 versus TMT-6-or TMT-10-labeled peptides are different owing to the different chemical properties of the tags and have been individually optimized so as to obtain as equal a distribution of peptide peaks across the entire gradient as possible (for example, see Fig. 3 ). The chromatograms of patient samples from the same study should look very similar. The corresponding gradient is used with synthetic peptides to assess performance of the system and column over time; peaks in this elution profile should also overlay (Fig. 3a) .
Specific experiments may prioritize throughput over depth; our protocol can flexibly accommodate those requirements. In cases in which larger numbers of samples are being compared, or when channels are reserved for a reference sample to facilitate quantitative comparison between experiments 8 , alternative reagents allow up to ten samples to be multiplexed, albeit with decrements in the number of proteins confidently identified and quantified (table 3) 44 . Eliminating off-line fractionation greatly increases sample analysis throughput, but decreases the depth of coverage by 5-8 fold (table 3) . By combining labeling with TMT-10 and eliminating off-line fractionation before LC-MS/MS, up to 600 proteins can be confidently identified and quantified (with two or more peptides/protein) by single-shot LC-MS/MS analysis using 50-cm columns with a 4.5-h gradient and packed with sub-2-µm beads (supplementary Fig. 4) .
